Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P100
Near historical high
vs 2Y Ago
48.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 3182.36% |
| Q3 2025 | 129.33% |
| Q2 2025 | 48.71% |
| Q1 2025 | 83.58% |
| Q4 2024 | -55.31% |
| Q3 2024 | 8.44% |
| Q2 2024 | 39.65% |
| Q1 2024 | -139.19% |
| Q4 2023 | 65.95% |
| Q3 2023 | 18.55% |
| Q2 2023 | -4.14% |
| Q1 2023 | -3.78% |
| Q4 2022 | -43.36% |
| Q3 2022 | 20.55% |
| Q2 2022 | 4.89% |
| Q1 2022 | -6.06% |
| Q4 2021 | -26.45% |
| Q3 2021 | 15.35% |
| Q2 2021 | -41.14% |
| Q1 2021 | 9.65% |
| Q4 2020 | -56.23% |
| Q3 2020 | -2.13% |
| Q2 2020 | 15.24% |
| Q1 2020 | -35.64% |
| Q4 2019 | 17.86% |
| Q3 2019 | -917.05% |
| Q2 2019 | 90.32% |
| Q1 2019 | -71.14% |
| Q4 2018 | 23.34% |
| Q3 2018 | -130.66% |
| Q2 2018 | 45.26% |
| Q1 2018 | -52.09% |
| Q4 2017 | 6.28% |
| Q3 2017 | -7.77% |
| Q2 2017 | -12.55% |
| Q1 2017 | -27.55% |
| Q4 2016 | -5.10% |
| Q3 2016 | -23.99% |
| Q2 2016 | 14.11% |
| Q1 2016 | -49.05% |